Federico Repetto, MD

@RepettoF_MD

PGY-3 at @MGBpathology @harvardmed 🔬| Dermatopathology fellow 2028-2029 @BIDMCpath @harvardmed @DanaFarber @BostonChildrens | Globetrotter 🌎🇦🇷✈️

Joined January 2023

323 Following 467 Followers 160 Posts

Latest posts 5

Pinned post

Federico Repetto, MD @RepettoF_MD Mar 15, 2024

THIS IS SURREAL!!!!
I matched to Mass General Brigham Pathology!!! Can’t wait to start this amazing adventure with this great group of people!!! 🥹😄🥳🍾

@BWHPath @MGHPathology

#Match2024 #PathTwitter #path2path

Federico Repetto, MD @RepettoF_MD Sep 15

Excited to share our new paper in Virchow Archiv! 🔬

We report an OGT-rearranged mesenchymal neoplasm of the palm with a novel OGT::C3orf62/MAPS fusion, expanding the molecular spectrum of this rare tumor.

A fun case with some interesting diagnostic and molecular twists 👇

Federico Repetto, MD @RepettoF_MD Aug 26

Thanks so much, @JLHornick, for this beautiful gift! A must-read for anyone interested in dermpath and surgical pathology. Excited to dive in! 📚🔬

Federico Repetto, MD @RepettoF_MD Aug 20

Excited to share our case published in @BloodPortfolio! 🩸

We highlight an unusual intramuscular relapse of BPDCN without active skin disease and stepwise TP53 progression superimposed on canonical TET2 founder alterations.

🔗 ashpublications.org/blood/article/…

ashpublications.org Blasting into muscle: isolated BPDCN relapse with second TP53 hit

Federico Repetto, MD @RepettoF_MD Aug 18

Great to see our work highlighted! 🙌

In our @JAMADerm study, EV–associated skin toxicities (particularly those occurring early in treatment) were associated with improved survival in patients with advanced urothelial carcinoma.

Excited to see where these findings lead! 🔬

Katy Beckermann Verified account @katy_beckermann Aug 6

Early EV rash may be associated with response

📈 EV-attributed skin toxicity: OS HR 0.46, PFS HR 0.60 at the 30-day landmark
🎯 Onset by day 15 carried the signal. Late rash did not.
⚠️ High-grade rash did not predict worse survival

Retrospective, and the rash group started healthier, ECOG 0 in 57% vs 33%.

Hope we continue to learn more as we understand dose intensity and response how we can best manage what can be severe skin toxicity. Topical and oral steroids, dose hold, and dose reductions.

👉 bit.ly/lee-ev-rash-20…

#BladderCancer #UrothelialCA #GUonc #ADC

View quoted post on X